|
|
Volumn 12, Issue 9, 2011, Pages 837-838
|
|
NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BORONIC ACID DERIVATIVE;
BORTEZOMIB;
PYRAZINE DERIVATIVE;
THALIDOMIDE;
COST BENEFIT ANALYSIS;
DRUG COST;
ECONOMICS;
EVIDENCE BASED MEDICINE;
HUMAN;
MULTIPLE MYELOMA;
NATIONAL HEALTH SERVICE;
NOTE;
PRACTICE GUIDELINE;
QUALITY ADJUSTED LIFE YEAR;
STANDARD;
TREATMENT OUTCOME;
UNITED KINGDOM;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BORONIC ACIDS;
COST-BENEFIT ANALYSIS;
DRUG COSTS;
EVIDENCE-BASED MEDICINE;
GREAT BRITAIN;
HUMANS;
MULTIPLE MYELOMA;
PRACTICE GUIDELINES AS TOPIC;
PYRAZINES;
QUALITY-ADJUSTED LIFE YEARS;
STATE MEDICINE;
THALIDOMIDE;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 80054815580
PISSN: None
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/s1470-2045(11)70202-9 Document Type: Note |
|
Times cited : (9)
|
|
References (0)
|
